Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists

Latest Soleus Capital Management, L.P. Stock Portfolio

$1.35Billion– No. of Holdings #90

Soleus Capital Management, L.P. Performance:
2024 Q1: 11.28%YTD: 11.28%2023: 11.29%

Performance for 2024 Q1 is 11.28%, and YTD is 11.28%, and 2023 is 11.29%.

About Soleus Capital Management, L.P. and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, Soleus Capital Management, L.P. reported an equity portfolio of $1.3 Billions as of 31 Mar, 2024.

The top stock holdings of Soleus Capital Management, L.P. are UTHR, EDAP, IOVA. The fund has invested 4.4% of it's portfolio in UNITED THERAPEUTICS CORP DEL and 3.9% of portfolio in EDAP TMS S A .

The fund managers got completely rid off RAYZEBIO INC, ATRICURE INC (ATRC) and SMITH & NEPHEW PLC (SNN) stocks. They significantly reduced their stock positions in SILK RD MED INC (SILK), TRANSMEDICS GROUP INC (TMDX) and VIKING THERAPEUTICS INC (VKTX). Soleus Capital Management, L.P. opened new stock positions in JASPER THERAPEUTICS INC (JSPR), BEIGENE LTD (BGNE) and KEROS THERAPEUTICS INC (KROS). The fund showed a lot of confidence in some stocks as they added substantially to CASTLE BIOSCIENCES INC (CSTL), IMMUNIC INC (IMUX) and INHIBRX INC (INBX).
Soleus Capital Management, L.P. Equity Portfolio Value
Last Reported on: 15 May, 2024

Soleus Capital Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Soleus Capital Management, L.P. made a return of 11.28% in the last quarter. In trailing 12 months, it's portfolio return was 29.98%.

New Buys

Ticker$ Bought
jasper therapeutics inc 34,853,100
beigene ltd 23,161,400
keros therapeutics inc 18,112,300
biogen inc 15,697,900
engene holdings inc13,560,000
inari med inc 13,290,500
enanta pharmaceuticals inc 10,136,300
cg oncology inc 9,564,540

New stocks bought by Soleus Capital Management, L.P.

Additions to existing portfolio by Soleus Capital Management, L.P.

Reductions

Ticker% Reduced
silk rd med inc -98.14
transmedics group inc -86.44
viking therapeutics inc -84.61
gsk plc -75.03
mereo biopharma group plc -73.23
denali therapeutics inc -63.85
nuvalent inc -59.96
protagonist therapeutics inc-58.43

Soleus Capital Management, L.P. reduced stake in above stock

Sold off

Ticker$ Sold
jasper therapeutics inc-7,788,200
harpoon therapeutics inc-9,330,650
rayzebio inc-46,417,500
vyne therapeutics inc-1,640,010
smith & nephew plc-12,827,000
atricure inc-13,997,400
si-bone inc-7,174,760
cvs health corp-4,698,120

Soleus Capital Management, L.P. got rid off the above stocks

Sector Distribution

Soleus Capital Management, L.P. has about 85% of it's holdings in Healthcare sector.

Sector%
Healthcare85
Others14.3

Market Cap. Distribution

Soleus Capital Management, L.P. has about 17.3% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
SMALL-CAP31.1
MID-CAP25
LARGE-CAP15.3
UNALLOCATED14.3
MICRO-CAP12.2
MEGA-CAP2

Stocks belong to which Index?

About 55.8% of the stocks held by Soleus Capital Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

Index%
RUSSELL 200050.7
Others44.2
S&P 5005.1
Top 5 Winners (%)%
JANX
janux therapeutics inc
265.2 %
VKTX
viking therapeutics inc
132.4 %
RGLS
regulus therapeutics inc
97.3 %
MNMD
mind medicine mindmed inc
91.5 %
SMFR
genedx holdings corp
87.7 %
Top 5 Winners ($)$
IOVA
iovance biotherapeutics inc
20.4 M
TEVA
teva pharmaceutical inds ltd
17.9 M
CELC
celcuity inc
12.5 M
JSPR
jasper therapeutics inc
12.4 M
VKTX
viking therapeutics inc
10.7 M
Top 5 Losers (%)%
ORGO
organogenesis hldgs inc
-29.9 %
HUM
humana inc
-24.2 %
TNGX
tango therapeutics inc
-23.4 %
IMVT
immunovant inc
-22.1 %
CVRX
cvrx inc
-20.1 %
Top 5 Losers ($)$
ORGO
organogenesis hldgs inc
-11.6 M
HUM
humana inc
-8.2 M
SRDX
surmodics inc
-5.5 M
TNGX
tango therapeutics inc
-3.3 M
IMVT
immunovant inc
-2.9 M

Soleus Capital Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Soleus Capital Management, L.P.

Soleus Capital Management, L.P. has 90 stocks in it's portfolio. About 31.5% of the portfolio is in top 10 stocks. ORGO proved to be the most loss making stock for the portfolio. IOVA was the most profitable stock for Soleus Capital Management, L.P. last quarter.

Last Reported on: 15 May, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions